Mirna adds $34.5 million

Mirna Therapeutics Inc. (Austin, Texas) raised $34.5 million in a series C round led by new investor Sofinnova Ventures, with participation from new investors New Enterprise Associates; Pfizer Ventures; Osage University Partners; Correlation Ventures; and undisclosed existing investors. Mirna's MRX34 is in preclinical testing to treat cancer. The compound is a synthetic mimic of the naturally occurring tumor suppressor miR-34 formulated with lipid-based nanoparticles. ...